Array Biopharma (ARRY) Tops Q4 EPS by 4c
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $7.90 -7.49%
EPS Growth %: -48.0%
Financial Fact:
Interest income: 70K
Today's EPS Names:
CBRS, MAYS, CRMT, More
EPS Growth %: -48.0%
Financial Fact:
Interest income: 70K
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Array Biopharma (NASDAQ: ARRY) reported Q4 EPS of ($0.17), $0.04 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $33.8 million versus the consensus estimate of $28.61 million.
Cash, Cash Equivalents and Marketable Securities as of June 30, 2017 were $235.1 million.
For earnings history and earnings-related data on Array Biopharma (ARRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
- Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
